- Home
- NEWS
- REGIONAL
- THIS WEEK'S PAPER
- BLOGS
- Multimedia
- OPINION
- A&E
- LISTS
- PEOPLE
- EVENTS
- Classifieds
- Subscribe
Pharmaceutical
Carmel firm gets FDA approval for lice treatment
January 18, 2011
IBJ StaffParaPRO LLC's treatment, called Natroba, has a potential U.S. market of 6 million to 12 million infected children annually.
MoreLilly imaging drug isn't ready for approval, FDA says
January 18, 2011
Eli Lilly and Co.’s experimental drug to help identify plaque in the brain tied to Alzheimer's disease isn't ready for approval,
according to U.S. regulators.
MoreEndocyte prices IPO stock
January 14, 2011
J.K. WallThe West Lafayette-based drug development firm intends to sell 6.15 million shares for $13 to $15 apiece. That would fetch
$80 million to $92 million.
MorePanel says Lilly’s Solpura isn’t ready for approval
January 12, 2011
Bloomberg NewsEli Lilly and Co. failed to win an FDA advisory panel’s recommendation to introduce the first pancreatic enzyme that
isn’t derived from pig parts.
MoreDeal could give Lilly full diabetes deck
January 12, 2011
J.K. WallEli Lilly and Co.'s diabetes partnership with Boehringer Ingelheim GmbH represents a new kind of disease-focused strategy
that some consultants think is key to pharma companies’ futures.
MoreUPDATE: Analysts praise Lilly diabetes deal with Boehringer
January 11, 2011
J.K. WallThe deal Eli Lilly and Co. announced Tuesday morning with Boehringer Ingelheim GmbH sounded a lot like a baseball trade—with
five drugs and payments to be named later—but analysts and investors generally liked what they heard.
MoreLilly agrees to pay up to $1.2B for diabetes drugs
January 11, 2011
J.K. WallA complex deal with Boehringer Ingelheim also gives the German company rights to two experimental Lilly insulins.
MoreLilly partner moves up timetable for diabetes drug
January 11, 2011
Bloomberg NewsAmylin Pharmaceuticals Inc., rebuffed twice in its bid for U.S. approval of a weekly diabetes drug, will meet its timetable
and submit a heart-safety study to regulators by the end of 2011, its CEO said.
MoreBill would let Indiana pharmacies collect old meds
January 10, 2011
Associated PressA bill authored by Republican Rep. Kevin Mahan of Hartford City would revise state law so that pharmacies could accept unused
prescription drugs from customers and dispose of them securely and safely.
MoreLilly's Solpura may lack data to prove effectiveness
January 10, 2011
Bloomberg NewsOutside advisers to the FDA will meet Jan. 12 to review whether the drug should be approved for people with pancreas insufficiency
caused by cystic fibrosis, chronic pancreatitis or other conditions.
MoreLilly, other big drugmakers shut out by FDA in 2010
January 3, 2011
IBJ Staff and Bloomberg NewsRegulators cleared 21 medicines, the fewest since 2007, for sale last year. It was the first time in a decade that Pfizer
Inc., the world's largest drugmaker, as well as Lilly, Merck & Co. and Bristol-Myers Squibb Co. were shut out at the same
time, according to agency records.
MoreRoche acquires Marcadia Biotech
December 30, 2010
Chris O'MalleyMarcadia Biotech Inc., a Carmel-based biopharmaceutical company founded by prominent scientists from Eli Lilly and Co. in
2006, has been acquired by Swiss life sciences giant Roche.
MoreGroup questions growth of pharmacy schools
December 29, 2010
J.K. WallTwo weeks before Manchester College announced a $35 million gift to help open a pharmacy school, a national trade group suggested
there are too many pharmacy schools already.
MoreIndiana Seed Fund makes 11th investment
December 23, 2010
IBJ StaffA $250,000 investment in Aarden Pharmaceuticals will go toward advancing tuberculosis therapy through the pre-clinical development
stage.
MoreLilly Endowment gives $35M to start pharmacy school
December 20, 2010
J.K. WallManchester College will use money to launch the state's third program offering doctorates in pharmacy.
MoreLilly suspends late-stage trial for melanoma drug
December 13, 2010
Bloomberg NewsEli Lilly and Co. suspended a late-stage clinical trial of a medicine for skin-cancer patients after 12 patients in the study
died.
MoreContrarians think it's new day for Lilly
December 1, 2010
J.K. WallThe trouble-free market approval obtained by Eli Lilly and Co. for a new underarm testosterone treatment brightened the company’s
outlook—at least for one of the few optimistic analysts covering the company.
MoreLilly, Acrux receive FDA approval for Axiron
November 24, 2010
IBJ Staff and Bloomberg NewsThe companies believe the underarm testosterone solution has the potential to realize sales of more than $1 billion a year
in the United States.
MoreLilly scores series of small victories
November 17, 2010
J.K. WallThe Indianapolis-based drugmaker finally won FDA approval for its antidepressant Cymbalta to treat chronic pain and fended
off a patent challenge to rising-star cancer drug Alimta, but got a ratings downgrade on its debt.
MoreDrugmakers seek Republican allies to defeat cost-cutting panel
November 15, 2010
Bloomberg NewsPharmaceutical firms led by Eli Lilly are trying to eliminate a government panel aimed at controlling Medicare spending seven
months after they supported the health-care overhaul that created it.
MoreStudy: Arthritis drug co-developed by Lilly shows promise
November 12, 2010
IBJ Staff and Bloomberg NewsLilly paid $90 million in 2009 to acquire the global rights to the treatment in a bid to beef up its pipeline of medications
for autoimmune diseases.
MoreAcquisition big step for Lilly Diagnostics
November 10, 2010
J.K. WallEli Lilly and Co.’s $800 million acquisition of Avid Radiopharmaceuticals Inc. is the biggest step yet in the drugmaker’s
attempt to add diagnostics to its product portfolio.
MoreDrugmaker restarts race to boost 'good' cholesterol
November 10, 2010
Bloomberg NewsMerck & Co. is betting it can succeed where Pfizer Inc. failed, with a new type of drug to combat heart disease by raising
good cholesterol levels. Indianapolis-based Eli Lilly and Co. is testing a similar pill.
MoreMoody's downgrades long-term ratings for Eli Lilly
November 9, 2010
Associated PressMoody's Investors Service on Monday lowered the long-term ratings of Lilly one notch, to A2 from A1, citing a wave of patent
expirations the drugmaker faces in coming years.
MoreLilly makes $300M deal for Philadelphia drug company
November 8, 2010
J.K. WallEli Lilly said it will acquire Avid Radiopharmaceuticals, maker of an experimental agent that could help identify patients
with Alzheimer's disease. The price could climb to $800 million if the agent is commercially successful.
More
Sponsored by
ADVERTISEMENT
on Facebook & Twitter
on Facebook & Twitter
 Follow IBJ's Tweets on these topics: |
||
| @IBJNews | @Propertylines | @IBJTheScore |
| @IBJArts | @IBJHealthcare | @IBJDining |
| @IBJLists | @IBJSmallbiz | |
ADVERTISEMENT
Back to TopCopyright © All Rights Reserved. Privacy Policy | Terms of Use.
Design, CMS, Hosting & Web Development :: ePublishing.
Additional Hosting & Delivery by
Can IBJ please stop referring to this property as "Kessler Mansion"? What a ridiculous title for the biggest, bloated, blight in our city. It's not a mansion. At best, it's an ideal site to shoot low-budget porn. Ahhh! Another business use!
Its stories like these that prove that a Ball State diploma is worth less than the paper that its printed on. A real institution of higher learning would have taken care of this long ago. No way should this crap be taught in a SCIENCE class.
It is such a shame that King Ballard has made Indianapolis into Chicago south with all of the rampant corruption.
How many of these 1,259 bills were actually heard and voted on on the floor vs how many were shot down in committee?
When a an arrogant young guy with essentially no experience and no qualifications for the job, was dropped into an Administrator position out of nowhere by his "mentor" in the Mayor's office things seemed fishy. Sometimes things are what they seem.